Hummingbird Bioscience eyes breakthrough in cancer treatment with ADCs
Piers Ingram, founder and CEO of Singapore-based Hummingbird Bioscience and its U.S. spin-off Callio Therapeutics, is quietly building a two-pronged strategy to reshape cancer treatment.
